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Abstract 
Background: The detection of Aspergillus spp. in endotracheal aspirate cultures of mechanically ventilated patients 
may reflect either colonization or infection. However, little is known about the prevalence and the impact on out‑
come of respiratory tract sample positive for Aspergillus during the acute respiratory distress syndrome (ARDS).
Methods: We conducted a monocentric, retrospective study over a 10‑year period (January 2006–December 2015) 
in the ICU of a university hospital. All consecutive adult patients with ARDS were included, and the diagnosis of inva‑
sive pulmonary aspergillosis was assessed using a previously validated algorithm.
Results: In total, 423 ARDS patients were included with 35 patients [8.3 %, 95 % CI (5.4–10.6)] having at least one 
respiratory tract sample positive for Aspergillus (Aspergillus+ patients) after a median delay of 3 days (1–11) following 
ICU admission. Comorbidities did not differ between Aspergillus+ and Aspergillus− patients except for more frequent 
immunosuppression in Aspergillus+ patients (40 vs. 22 %; p = 0.02). There was no difference between Aspergil‑
lus− and Aspergillus+ patients regarding in‑ICU mortality, ventilator‑free days at day 28, and incidence of ventilator‑
associated pneumonia, but need for renal replacement therapy was higher in Aspergillus+ patients than in others 
(49 vs. 27 %; p = 0.01). Seventeen [4.0 %, 95 % CI (2.1–5.9)] patients had putative/proven aspergillosis. After adjust‑
ing on covariates associated with ICU mortality, putative/proven aspergillosis was associated with in‑ICU mortality 
[aOR = 9.58 (1.97–46.52); p = 0.005], while Aspergillus colonization was not [aOR = 0.64 (0.21–1.99); p = 0.44].
Conclusions: Eight percent of ARDS patients had Aspergillus spp.‑positive respiratory tract cultures. These had a 
higher risk of mortality only when categorized as having putative or proven invasive pulmonary aspergillosis.
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Background
Invasive pulmonary aspergillosis (IPA) has been reported 
chiefly in immunocompromised patients with prolonged 
neutropenia, organ and allogeneic stem cell transplanta-
tion, prolonged corticosteroids use or severe inherited 
immunodeficiency [1]. However, in the past decade, 
definite cases of IPA have also been reported in intensive 
care unit (ICU) patients having none of the previously 
defined host risk factors for IPA [2], but other associated 
illnesses including advanced cirrhosis [3, 4], H1N1 Influ-
enza infection [5] or chronic obstructive pulmonary dis-
ease (COPD) [4–7]. In one study, the prevalence of IPA 
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reached 6 % in a cohort of patients without malignancy 
hospitalized in a medical ICU [4]. Endotracheal aspirate 
cultures growing Aspergillus spp. have been recorded 
in 1–2  % of mechanically ventilated ICU patients hav-
ing no predisposing factors and may reflect either colo-
nization or infection [8–11]. A recent clinical algorithm 
developed by Blot et  al. demonstrated favorable operat-
ing characteristics to discriminate Aspergillus respira-
tory tract colonization from IPA in ICU patients, whereas 
the European Organization for Research and Treatment 
of Cancer/Mycosis Study Group (EORTC/MSG) criteria 
failed to adequately categorize patients in the absence of 
conventional risk factors [1].
The acute respiratory distress syndrome (ARDS) [12] 
occurs in about 10  % of ICU patients and is associated 
with a high mortality of 35  % [13]. Respiratory tract 
Aspergillus colonization was shown to be more frequent 
in ARDS than in other critically ill patients [14]. An 
autopsy study of 64 patients with ARDS revealed that 8 
of them (13 %) had died with pulmonary lesions of IPA 
[15]. However, the burden of IPA during ARDS has been 
poorly studied and little is known on the prevalence of 
Aspergillus respiratory tract colonization and IPA during 
ARDS, as well as on the prognosis of IPA in this setting. 
In this monocenter retrospective study we aimed at: (1) 
assessing the prevalence, (2) reporting the clinical char-
acteristics, and (3) evaluating the impact on outcome of 
Aspergillus-positive lower respiratory tract specimen in 
ARDS patients.
Methods
We conducted a monocenter retrospective study in the 
24-bed medical ICU of a tertiary referral center (Henri 
Mondor Hospital, Créteil, France). All consecutive adult 
(>18  years) patients admitted in the ICU for ARDS 
according to the Berlin definition criteria (within 48  h 
of admission) and receiving invasive mechanical ven-
tilation over a 10-year period (January 2006 to Decem-
ber 2015) were included [12]. Exclusion criteria were 
as follows: previously known lung interstitial disease or 
tumoral infiltration, chronic respiratory failure requiring 
long-term oxygen therapy, pure cardiogenic pulmonary 
edema, mild ARDS treated with noninvasive ventilation 
only, proven or suspected invasive pulmonary aspergil-
losis under antifungal therapy upon ARDS diagnosis and 
patients for whom no endobronchial sampling had been 
obtained.
All respiratory tract samples (plugged telescoping 
catheter, tracheal aspirate or bronchoalveolar fluid) per-
formed for microbiological examination were analyzed. 
Galactomannan antigen (GM) detection in plasma and 
in bronchoalveolar lavage (BAL) fluid was performed 
at the discretion of the managing physician. An optical 
density ratio of 0.5 or greater for GM in serum and of 1.0 
or greater for BAL fluid was considered positive. Chest 
CT scan and cerebral or facial scan were not routinely 
performed.
Definition of infection and categorization of patients
Patients were categorized into two groups: those with 
one or more respiratory tract sample positive in cul-
ture for Aspergillus spp. (Aspergillus+ patients) during 
the ICU stay and those without such positive sample 
(Aspergillus− patients). The former group was further 
split into three categories depending on the probabil-
ity of IPA according to the clinical algorithm proposed 
by Blot et al. [16]: (A) proven IPA (microscopic analysis 
on sterile material: histopathologic, cytopathologic or 
direct microscopic examination of a specimen obtained 
by needle aspiration or sterile biopsy in which hyphae are 
seen accompanied by evidence of associated tissue dam-
age; isolation of Aspergillus from culture of a specimen 
obtained by lung biopsy); (B) putative IPA in case of (1) 
Aspergillus-positive lower respiratory tract specimen cul-
ture (entry criterion) with (2) compatible signs and symp-
toms (one of the following: fever refractory to at least 
3  days of appropriate antibiotic therapy, recrudescent 
fever after a period of defervescence of at least 48 h while 
still on antibiotics and without other apparent cause, 
pleuritic chest pain, pleuritic rub, dyspnea, hemoptysis, 
worsening respiratory insufficiency in spite of appropri-
ate antibiotic therapy and ventilatory support) and (3) 
abnormal medical imaging by portable chest X-ray or 
CT scan of the lungs, and either (4a) a host risk factor 
(one of the following conditions: neutropenia (absolute 
neutrophil count <500 G/L) preceding or at the time of 
ICU admission, underlying hematological or oncological 
malignancy treated with cytotoxic agents, glucocorticoid 
treatment (prednisone equivalent >20 mg/day), congeni-
tal or acquired immunodeficiency) or (4b) a semiquan-
titative Aspergillus-positive culture of BAL fluid (+ or 
+++), without bacterial growth together with a posi-
tive cytological smear showing branching hyphae or (C) 
Aspergillus respiratory tract colonization when ≥1 cri-
terion necessary for a diagnosis of putative IPA was not 
met (Tables 1, 2). 
Collection of data and definitions
Demographics and clinical characteristics upon ICU 
admission and during ICU stay were abstracted from 
the medical charts of all patients. Immunosuppression 
was defined by one of the following conditions: neutro-
penia (absolute neutrophil count <500 G/L) preceding or 
at the time of ICU admission, underlying hematological 
or oncological malignancy treated with cytotoxic agents, 
glucocorticoid treatment (prednisone equivalent >20 mg/
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day for more than 4  weeks), congenital (e.g., chronic 
granulomatous disease, hyper-IgE syndrome [17]) or 
acquired (e.g., AIDS [18]) immunodeficiency. Patient 
initial severity was assessed using the Simplified Acute 
Physiology Score II (SAPS II) [19] and Logistic Organ 
Dysfunction (LOD) [20] scores. ARDS was categorized as 
mild, moderate or severe according to the lowest PaO2/
FiO2 ratio obtained within 48  h of ICU admission [12]. 
Shock was defined as need for vasopressor (epinephrine 
or norepinephrine) at a dose higher than 1 mg/h for more 
than 2 h. Outcome variables included the use of adjuvant 
therapies for ARDS (i.e., neuromuscular blocking agents, 
nitric oxide inhalation, prone positioning or venovenous 
extracorporeal membrane oxygenation), the need for 
renal replacement therapy or vasopressors, the adminis-
tration of corticosteroids, the number of ventilator-free 
days at day 28, the duration of ICU stay, the incidence of 
ventilator-associated pneumonia and in-ICU mortality.
All chest CT scans performed in Aspergillus+ patients 
were reviewed by two pulmonologists (FS and NDP) 
blinded to the final Aspergillus classification and out-
come. Elementary lesions including alveolar consolida-
tion, lung nodules, ground-glass opacities, halo sign, 
cavitation and pleural effusion were recorded.
Patient’s management
ARDS patients received mechanical ventilation using 
a standardized protective ventilation strategy [21, 22]. 
Tracheal suction was performed using a closed system. 
Other treatments including neuromuscular blocking 
agents [23], nitric oxide inhalation, prone positioning 
[24] and venovenous extracorporeal membrane oxy-
genation were administered depending on the severity of 
ARDS [25].
Antifungal therapy (voriconazole, caspofungin or 
liposomal amphotericin B) was administered at the 
Table 1 Demographics and  clinical characteristics upon  ICU admission of  ARDS patients with  (Aspergillus+) or with-
out (Aspergillus−) one or more respiratory tract sample positive for Aspergillus spp.
ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease; continuous variables are shown as median (interquartile range 25–75); 








Age (years) 62 (50–72) 62 (50–72) 62 (49–72) 0.82
Gender (male) 282 (67) 258 (66) 24 (69) 0.85
Previously known aspergillosis 8 (2) 7 (2) 1 (3) 0.50
Immunosuppression 100 (24) 86 (22) 14 (40) 0.023
COPD 48 (11) 44 (11) 4 (11) >0.99
Inhaled steroids 16 (4) 15 (4) 1 (3) >0.99
Liver cirrhosis 44 (10) 42 (11) 2 (6) 0.56
Chronic renal failure 16 (4) 15 (4) 1 (3) >0.99
Diabetes mellitus 85 (20) 79 (20) 6 (17) 0.83
SAPS II 53 (37–69) 53 (38–70) 51 (34–68) 0.65
LODS 8 (6–12) 8 (6–12) 7 (5–11) 0.26
Main ARDS risk factors
 Pulmonary infection 202 (48) 173 (45) 29 (83) <0.0001
 Aspiration 154 (36) 147 (38) 7 (20) 0.043
 Non‑pulmonary sepsis 87 (21) 84 (22) 3 (9) 0.080
 Drug overdose 12 (3) 11 (3) 1 (3) >0.99
Delay first respiratory symptom—admission, days 2 (0–5) 2 (0–5) 2 (0–8) 0.41
Temperature > 38.3 °C 220 (52) 199 (51) 21 (60) 0.38
Noninvasive ventilation 69 (16) 65 (17) 4 (11) 0.63
Berlin classification 0.38
 Mild 113 (27) 104 (27) 9 (26)
 Moderate 162 (38) 144 (37) 18 (51)
 Severe 148 (35) 140 (36) 8 (23)
PaO2/FiO2 ratio (mm Hg) 106 (77–163) 106 (78–162) 114 (76–173) 0.84
Shock 325 (77) 297 (76) 28 (80) 0.83
Serum creatinine (µmol/L) 120 (82–180) 120 (82–177) 128 (82–207) 0.76
Page 4 of 11Contou et al. Ann. Intensive Care  (2016) 6:52 
discretion of the managing physician and not initiated on 
the sole basis of a positive GM in serum or in BAL fluid.
Statistical analysis
Continuous variables are reported as median [25th–75th 
percentiles] or mean ± standard deviation (SD) and com-
pared as appropriate. Categorical variables are reported 
as numbers and percentages [95  % confidence interval 
(95  % CI)] and compared as appropriate. There was no 
imputation for missing data, except for data missing from 
comorbidities, which were then considered as absent. 
Factors associated with ICU mortality were deter-
mined by univariable and multivariable backward logis-
tic regression analyses. Independent variables with a p 
value <0.10 in univariable analysis were entered into the 
multivariable model, with backward elimination of vari-
ables displaying a p value greater than 0.05. Interactions 
between variables were assessed using the Mantel–Haen-
szel test. Analyses were conducted using the SPSS Base 
21.0 statistical software package (SPSS Inc., Chicago, IL).
Results
Prevalence of Aspergillus+ respiratory tract samples 
during ARDS
Over the 10-year study period, 423 patients were admit-
ted for ARDS, of whom 35 [8.3 %, 95 % CI (5.4–10.6)] had 
at least one respiratory tract sample positive for Aspergil-
lus spp. (Aspergillus+ patients) (Fig. 1; Table 1).
Among 17 (49  %) immunocompromised Aspergillus+ 
patients, one had proven IPA, 11 had putative IPA, and 
5 were categorized as having respiratory tract coloniza-
tion. Conversely, among 18 (51  %) non-immunocom-
promised Aspergillus+ patients, 5 had putative IPA and 
13 had colonization (Fig.  1; Table  2). The overall preva-
lence of proven/putative aspergillosis was 4.0 % [95 % CI 
(2.1–5.9)].
Presentation of ARDS patients with Aspergillus‑positive 
respiratory tract samples
Comorbidities did not differ between Aspergillus+ 
and Aspergillus− patients except for more frequent 
Table 2 Classification of ARDS patients with one or more respiratory tract sample positive for Aspergillus spp., according 
to the Blot algorithm, adapted from Blot et al. [16]
a Hematological malignancies (n = 7, including lymphoma (n = 5), acute leukemia (n = 2), one of whom required allogeneic bone marrow transplant), solid organ 
transplant (n = 6), gastric cancer (n = 1), HIV infection (n = 1), neutropenia of unknown cause (n = 1) and connective tissue disease under corticosteroid treatment 
(n = 1)
b p = 0.018 and c p = 0.015 (Fisher’s exact test) for comparison between immunosuppressed and non-immunosuppressed patients; continuous variables are shown 





Proven invasive pulmonary aspergillosis (n = 1) 1 (6) 0 (0)
Putative invasive pulmonary aspergillosis (n = 16) 11 (65) 5 (28)b
1. Aspergillus‑positive lower respiratory tract specimen culture 17 18
2. Compatible signs and symptoms
Fever refractory to at least 3 d of appropriate antibiotic therapy 3 1
Recrudescent fever after a period of defervescence of at least 48 h while still on antibiotics and 
without other apparent cause
1 0
Pleuritic chest pain 1 0
Pleuritic rub 0 0
Dyspnea 0 0
Hemoptysis 1 0
Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory 
support
6 11
3. Abnormal medical imaging by portable chest X‑ray or CT scan of the lungs 17 18
4a. Host risk factors 17 0
Neutropenia (absolute neutrophil count < 0.5 G/L) preceding or at the time of ICU admission 4 0
Underlying hematological or oncological malignancy treated with cytotoxic agents 5 0
Glucocorticoid treatment (prednisone equivalent >20 mg/d and >4 weeks) 1 0
Congenital or acquired immunodeficiency 7 0
4b. Semiquantitative Aspergillus‑positive culture of BAL fluid (+ or ++), without bacterial growth 
together with a positive cytological smear showing branching hyphae
4 6
Aspergillus respiratory tract colonization (n = 18) 5 (29) 13 (72)c
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immunosuppression in the former group (Table  1). The 
two groups did not differ regarding clinical presentation 
and severity of illness upon ICU admission, as assessed 
by SAPS II, LODS and ARDS severity. Regarding the 
main ARDS risk factors retrieved, infective pneumonia 
was significantly more frequent (while aspiration pneu-
monitis was less frequent) in Aspergillus+ patients than 
in others (Table 1).
Among the 35 patients of the Aspergillus+ group, 
27 (77  %) had a GM measurement performed in both 
plasma and BAL fluid. Plasma GM measurements were 
not significantly different between patients with proven/
putative IPA and those with Aspergillus spp. colonization 
(7/15, 47 % vs. 2/12, 17 %, p =  0.22). In contrast, when 
measured in BAL fluid, GM was more frequently posi-
tive in patients with proven/putative IPA than in those 
with Aspergillus colonization (8/15, 53  % vs. 0/12, 0  %, 
p = 0.003) (Table 3).
Chest CT scans were obtained in 60  % (n  =  21/35) 
of patients of the Aspergillus+ group during ICU stay 
(Table  4; Fig.  2) and displayed no significant difference 
between patients categorized as having proven/puta-
tive aspergillosis (n = 13/21) and those with Aspergillus 
colonization (n = 8/21). Of note, while lung nodules were 
observed in 67 % of cases, other chest CT scan patterns 
suggestive of IPA, including lung cavitation and halo sign, 
were detected in only 14 % of cases. Alveolar consolida-
tions, consistent with the underlying ARDS, were present 
in 90 % of cases.
Management and outcome of ARDS patients 
with Aspergillus‑positive respiratory tract samples
The median number of collected samples was 3 (2–7) per 
patient, and the median delay between ICU admission 
and the first respiratory tract sample positive for Asper-
gillus spp. was 3 days (1–11) (Table 5). There were no dif-
ferences between Aspergillus− and Aspergillus+ patients 
regarding duration of ICU stay, in-ICU mortality, num-
ber of ventilator-free days at day 28 and incidence of 
ventilator-acquired pneumonia and of shock. In contrast, 
the need for renal replacement therapy was almost twice 
as high in Aspergillus+ patients than in others (Table 5). 
Within the Aspergillus+ group, fifteen patients received 
an antifungal treatment during ICU stay (voriconazole, 
n =  12; liposomal amphotericin B, n =  3; caspofungin, 
n  =  2; combination therapy, n  =  3), including the sole 
ARDS patients over a 10-year period
N = 423
Aspergillus – patients
N = 388 (92%)
Aspergillus + patients
N = 35 (8%)
No immunosuppression
N = 18
Proven IPA n = 0
Putative IPA n = 5
Aspergillus respiratory tract colonization n = 13
Immunosuppression
N = 17
Proven IPA n = 1
Putative IPA n = 11
Aspergillus respiratory tract colonization n = 5
Fig. 1 Flowchart of patients with the acute respiratory distress syndrome (ARDS) included in the study. Eight percent of patients (n = 35) had a 
respiratory tract culture positive for Aspergillus spp., including both immunosuppressed (n = 17) and non‑immunosuppressed (n = 18) patients. The 
diagnostic probability of invasive pulmonary aspergillosis was assessed using the algorithm of Blot et al. [16]
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patient with proven IPA, 10 over 16 patients with puta-
tive IPA and 4 over 18 patients with Aspergillus respira-
tory tract colonization.
The association between Aspergillus status, as catego-
rized with the Blot et al. algorithm, and in-ICU mortal-
ity was assessed by logistic regression analysis. Both in 
univariable analysis [OR = 7.98 (1.80–35.36), p = 0.006)] 
and after adjusting for covariates significantly associated 
with ICU mortality, putative/proven IPA was strongly 
associated with in-ICU mortality [aOR  =  9.58 (1.97–
46.52), p = 0.005], while Aspergillus colonization was not 
[aOR  =  0.64 (0.21–1.99), p  =  0.44] (Table  6). Of note, 
within the putative/proven IPA subgroup (n = 17), 10/12 
immunocompromised and 5/5 non-immunocompro-
mised patients died in the ICU.
Discussion
We herein report Aspergillus-positive lower respiratory 
tract specimen culture in an 8  % prevalence of patients 
with ARDS, half of whom had putative or proven IPA. 
Immunosuppression and pneumonia were more frequent 
among patients having at least one positive sample for 
Aspergillus. Immunocompromised ARDS patients were 
more frequently categorized as having putative or proven 
IPA, while non-immunocompromised patients were 
more likely categorized as having Aspergillus respira-
tory tract colonization. Importantly, patients with one 
or more positive respiratory tract sample for Aspergil-
lus had a worse outcome than others only when catego-
rized as having putative/proven IPA according to the Blot 
algorithm.
The current series is, to the best of our knowledge, the 
largest one to focus on Aspergillus-positive respiratory 
tract samples in ARDS patients. The 8  % prevalence of 
patients having at least one positive sample for Aspergil-
lus, in our population with ARDS, is significantly higher 
than the 1 % rate prospectively reported by Bassetti et al. 
in unselected mechanically ventilated patients, suggest-
ing ARDS is a risk factor for Aspergillus respiratory colo-
nization and/or infection [14]. Four percent of our ARDS 
patients (n = 17/423) were eventually classified as having 
proven or putative IPA, which is less than the 13 % preva-
lence of proven IPA that was previously reported in an 
autopsy study of 64 patients with ARDS [15], likely due to 
differences in case-mix and methods between this study 
and ours. Such figures are consistent with the fact that 
the Blot et  al. algorithm was previously shown to have 
61  % specificity and positive predictive value and 92  % 
sensitivity and negative predictive value, implying that 
its ability to exclude IPA might be better than in diag-
nosing it [16, 26]. Strikingly, the median delay between 
the first respiratory sample positive for Aspergillus spp. 
and mechanical ventilation initiation was 3  days, con-
sistent with a previous study in mechanically ventilated 
Table 3 Serum and bronchoalveolar lavage fluid galactomannan antigen according to the probability of invasive pulmo-
nary aspergillosis (Blot et al. algorithm [16])
BAL bronchoalveolar lavage









Positive serum galactomannan 9 (33) 7 (47) 2 (17) 0.22
Positive BAL fluid galactomannan 8 (30) 8 (53) 0 (0) 0.003
Table 4 Chest CT scan patterns in patients (n = 21) categorized as having proven/putative invasive pulmonary aspergil-
losis or Aspergillus colonization, according to the Blot algorithm [16]








Pulmonary infiltrates 21 (100) 13 (100) 8 (100) >0.99
Alveolar consolidation 19 (90) 11 (85) 8 (100) 0.11
Lung nodules 15 (71) 8 (61) 7 (87) 0.33
Ground‑glass opacities 14 (67) 10 (77) 4 (50) 0.34
Cavitation 3 (14) 1 (8) 2 (25) 0.53
Halo sign 3 (14) 2 (15) 1 (12) >0.99
Pleural effusion 12 (57) 8 (61) 4 (50) 0.67
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non-ARDS patients [11], suggesting that respiratory tract 
colonization by Aspergillus spores had occurred prior 
to ARDS onset. The combination of ARDS-associated 
alveolar damage and associated local immune dysregula-
tion [27], together with sepsis-induced immunosuppres-
sion [28], might, through alterations in innate immunity 
and antigen presentation processes [29], account for the 
development of IPA in previously colonized patients. 
Other previously described conditions at risk of IPA in 
critically ill non-immunosuppressed patients include 
COPD, present in only 11 % of our Aspergillus+ group, as 
compared to 31 % in a large series and, to a lesser extent, 
cirrhosis and corticosteroids, observed in less than 10 % 
of cases [6]. Surprisingly, however, corticosteroid admin-
istration was not associated with mortality in a recent 
series of mechanically ventilated patients with proven 
or putative Aspergillosis [6]. Although we found a trend 
toward more high-dose steroids administration in the 
Fig. 2 Chest CT scan images in patients with ARDS and one or more respiratory tract culture positive for Aspergillus spp., categorized as having 
putative invasive pulmonary aspergillosis (IPA) or Aspergillus colonization [16]. CT scan slices depicted a ARDS‑typical bilateral basal consolidations, 
together with ground‑glass opacities (left panel) and left anterior pneumothorax (right panel) in a patient categorized as having putative IPA; b right 
upper lobe cavitation (left panel), together with nodular lesions (right panel) in a patient with necrotizing group A Streptococcus, categorized as hav‑
ing Aspergillus respiratory tract colonization; and c nodular lesions with ground‑glass opacities (left panel) and alveolar consolidations (right panel) in 
a patient categorized as having putative IPA
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Table 5 Management and outcomes of ARDS patients with (Aspergillus+) or without (Aspergillus−) one or more respira-
tory tract sample positive for Aspergillus spp.
ECMO extracorporeal membrane oxygenation, BAL bronchoalveolar lavage
a Hydrocortisone 200 mg/day









 Number of endobronchial samples 4.0 (2.0–7.0) 3.5 (2.0–7.0) 4.5 (2.7–9.2) 0.019
 Including BAL 211 (48) 181 (45) 30 (86) <0.0001
Duration of ICU stay (days) 12 (6–22) 12 (6–22) 14 (7–35) 0.14
Ventilator‑free days at day 28 (days) 0 (0–17) 0 (0–22) 0 (0–16) 0.19
Ventilator‑acquired pneumonia 146 (35) 135 (35) 11 (31) 0.85
Treatment
 Prone position 169 (40) 153 (40) 16 (46) 0.48
 Nitric oxide inhalation 117 (28) 108 (28) 9 (26) 0.85
 Paralyzing agents 380 (92) 348 (92) 32 (91) >0.99
 ECMO 21 (5) 18 (5) 3 (9) 0.40
Shock 350 (83) 321 (83) 29 (83) >0.99
Renal replacement therapy 122 (29) 105 (27) 17 (49) 0.011
Corticosteroids
 “Stress‑dose” steroidsa 144 (34) 134 (34) 10 (29) 0.58
 “High‑dose” steroidsb 96 (23) 84 (22) 12 (34) 0.094
In‑ICU mortality 209 (50) 188 (48) 21 (60) 0.22
Table 6 Univariable and  multivariable logistic regression analyses of  factors associated with  ICU mortality in  ARDS 
patients
IPA invasive pulmonary aspergillosis
a As prescribed for a suspicion of invasive pulmonary aspergillosis; the Hosmer–Lemeshow goodness of fit test showed good calibration of the model (p = 0.28); the 
area under the curve of the model is 0.78 (0.73–0.82); OR (95 % CI), odds ratio (95 % confidence interval); aOR, adjusted odds ratio
n Death
n (%)
Univariable analysis Multivariable analysis
OR (95 % CI) p aOR (95 % CI) p
Age (years) – – 1.02 (1.01–1.03) <0.0001 1.02 (1.00–1.03) 0.029
Year of inclusion – – 0.89 (0.82–0.95) <0.001 – –
Liver cirrhosis
 Yes 44 31 (70.5) 2.69 (1.37–5.31) 0.004 2.62 (1.24–5.54) 0.012
 No 379 178 (47.0) 1 1
Immunosuppression
 Yes 100 58 (58.0) 1.57 (1.00–2.47) 0.050 1.83 (1.08–3.11) 0.024
 No 323 151 (46.7) 1 1
PaO2/FiO2 ratio (mmHg) – – 0.99 (0.99–0.99) <0.0001 0.99 (0.99–0.99) <0.0001
SAPS II – – 1.03 (1.02–1.04) <0.0001 1.02 (1.00–1.03) 0.018
LODS – – 1.19 (1.13–1.25) <0.0001 1.12 (1.05–1.20) <0.001
Antifungal treatmenta
 Yes 17 12 (70.6) 2.55 (0.88–7.36) 0.084 – –
 No 406 197 (48.5) 1
Blot et al. algorithm[16]
 No Aspergillus spp. colonization 388 188 (48.5) 1 – 1 –
 Aspergillus spp. colonization 18 6 (33.3) 0.53 (0.20–1.45) 0.22 0.64 (0.21–1.99) 0.44
 Putative or proven IPA 17 15 (88.2) 7.98 (1.80–35.36) 0.006 9.58 (1.97–46.52) 0.005
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Aspergillus+ group, their relationship with subsequent 
IPA and death could not be assessed in our study due to 
its limited statistical power.
The recent clinical algorithm proposed by Blot et  al. 
for discriminating between ICU patients with Aspergillus 
respiratory tract colonization and those with IPA, allows 
for categorizing non-immunocompromised patients as 
having putative IPA, provided semiquantitative culture 
of BAL fluid is positive for Aspergillus, together with a 
positive cytological smear showing branching hyphae 
[16]. This criterion (4b) becomes indeed crucial in non-
immunocompromised ARDS patients who all meet, by 
definition, the radiological criterion of the Blot algorithm 
(criterion 3), while both the relevance and reproducibility 
of several of the clinical criteria (e.g., dyspnea, pleuritic 
chest pain, pleuritic rub) can be questioned in critically 
ill mechanically ventilated patients. Nevertheless, and 
as expected, immunosuppression was strongly associ-
ated with proven/putative IPA in our series; however, it 
is noteworthy that non-immunocompromised patients 
accounted for one-third of patients classified as having 
probable infection, all of whom (n = 5/5) eventually died, 
suggesting putative IPA portends a dismal prognosis even 
in non-immunocompromised patients.
Although the purpose of our study was not to evaluate 
the performance value of GM antigen measurement, our 
results suggest that its detection is more efficient in BAL 
fluid than in plasma to discriminate between proven/
putative IPA and Aspergillus colonization, in line with 
a previous prospective study conducted in non-ARDS 
critically ill patients [30]. In the context of ARDS patients 
with a positive culture for Aspergillus, a positive GM test 
in BAL fluid may be a helpful tool to reinforce the diag-
nostic suspicion of IPA and may thus incite clinicians to 
start antifungal therapy.
While the number of chest CT scans available in the 
current study was limited, our results suggest that, in the 
particular context of ARDS, its diagnostic yield to dis-
criminate between putative aspergillosis and Aspergillus 
colonization is limited, most patients exhibiting non-spe-
cific findings such as alveolar consolidations.
In our series, the overall positivity of one or more res-
piratory sample for Aspergillus was not significantly 
associated with higher in-ICU mortality. Still, the risk 
of in-ICU mortality was significantly higher in ARDS 
patients with proven/putative IPA, as opposed to those 
with Aspergillus colonization, and as compared to those 
having no positive respiratory tract culture for Asper-
gillus, even after adjusting on significantly associated 
covariables. The benefit/risk ratio of antifungal therapy 
has not been assessed in ICU patients when categorized 
as having proven/putative IPA according to the recently 
proposed algorithm [16]. Our findings of a higher in-ICU 
mortality among a cohort of ARDS patients suggest that 
the initiation of such treatment should be considered in 
this specific subgroup, including non-immunocompro-
mised patients, who also exhibited a strikingly high ICU 
mortality (n  =  5/5 died). Of note, a previous observa-
tional study in critically ill COPD patients having puta-
tive IPA reported no improvement in ICU and long-term 
mortality in patients receiving antifungal treatment as 
compared to others, suggesting the severity of the under-
lying diseases was a key prognostic factor [7]. Strikingly, 
in the current series, six patients of the putative IPA sub-
group (n =  16) did not receive an antifungal treatment, 
reflecting the fact that the criteria on which such treat-
ment should be initiated in patients having Aspergillus 
spp.-positive respiratory tract samples are not standard-
ized yet.
Our study has a number of limitations. First, due to its 
monocentric design, our results may not be applicable 
to other centers, thereby limiting their generalizability, 
since risk exposure to Aspergillus, prevalence of coloni-
zation and subsequent IPA may vary between centers. 
Moreover, the number and the type of respiratory tract 
samples performed were not standardized over the study 
period, potentially hampering the isolation of Aspergil-
lus spp. in patients having had limited microbiological 
investigations. Second, this was a retrospective study 
with possible associated errors in data abstraction. How-
ever, due to the relatively low frequency of IPA, prospec-
tive studies in the specific subgroup of ARDS patients 
would be hardly feasible due to the low rate of Aspergil-
lus colonization [8]. Third, our patients were admitted 
over a 10-year period, with inherently associated selec-
tion bias related to variations in coding habits between 
years. Moreover, during this relatively long time period, 
exposure to Aspergillus spores might have varied due to 
environmental factors. However, we found no association 
between the year of ICU admission and the risk of having 
one or more respiratory tract sample positive for Asper-
gillus spp. Fourth, several known prognostic factors for 
ARDS, including pulmonary artery pressure level or right 
ventricular dysfunction [31], were not available due to 
the retrospective nature of the study. Last, due to the lim-
ited number of patients having had a chest CT scan per-
formed (n = 21/35), our study does not allow for drawing 
definite conclusions regarding the performance of chest 
CT scan in discriminating between putative aspergillosis 
and Aspergillus colonization in the context of ARDS.
Conclusions
We report a prevalence of 8  % of Aspergillus-positive 
lower respiratory tract specimen culture and 4  % of 
proven or putative IPA during ARDS. Immunocompro-
mised ARDS patients were more likely to be categorized 
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as having a putative or proven IPA, while non-immuno-
compromised patients were more frequently classified as 
having Aspergillus respiratory tract colonization. Immu-
nosuppression and pneumonia were associated with hav-
ing at least one positive sample for Aspergillus. In this 
cohort of ARDS patients, having one or more positive 
sample for Aspergillus had no impact on outcome when 
classified as a mere respiratory tract colonization. In con-
trast, patients classified as having putative/proven IPA 
had a higher risk of in-ICU mortality, suggesting antifun-
gal treatment should be assessed in this subgroup.
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